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Abstract 
Context: Prader-Willi syndrome (PWS) is a complex hypothalamic disorder, combining 
hyperphagia, hypotonia, intellectual disability, and pituitary hormone deficiencies. 
Annual mortality of patients with PWS is high (3%). In half of the patients, the cause of 
death is obesity related and/or of cardiopulmonary origin. Health problems leading to 
this increased mortality often remain undetected due to the complexity and rareness of 
the syndrome.
Objective: To assess the prevalence of health problems in adults with PWS retrospectively.
Patients, Design, and Setting: We systematically screened 115 PWS adults for 
undiagnosed health problems. All patients visited the multidisciplinary outpatient clinic 
for rare endocrine syndromes at the Erasmus University Medical Center, Rotterdam, 
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examinations, biochemical measurements, polygraphy, polysomnography, and 
radiology.
Main outcome measures: Presence or absence of endocrine and nonendocrine 
comorbidities in relation to living situation, body mass index, genotype, and demographic 
factors.
Results: Seventy patients (61%) had undiagnosed health problems, while 1 in every 
4 patients had multiple undiagnosed health problems simultaneously. All males and 
93% of females had hypogonadism, 74% had scoliosis, 18% had hypertension, 19% had 
hypercholesterolemia, 17% had type 2 diabetes mellitus, and 17% had hypothyroidism. 
Unfavorable lifestyles were common: 22% exercised too little (according to PWS criteria) 
and 37% did not see a dietitian.
Conclusions: Systematic screening revealed many undiagnosed health problems in 
PWS adults. Based on patient characteristics, we provide an algorithm for diagnostics 
and treatment, with the aim to prevent early complications and reduce mortality in this 
vulnerable patient group.
Freeform/Key Words:  Prader-Willi syndrome, cardiovascular system, missed diagnosis, comorbidity, failure to 
rescue, health care
Introduction
Prader-Willi syndrome (PWS) is a rare genetic, neuroendo-
crine condition caused by the absence of a normal paternal 
contribution to the 15q11-13 region. It is most commonly 
caused by a paternal deletion (65–75%) or a maternal 
uniparental disomy 15 ([mUPD], 20–30%). In the minority 
of cases, PWS is caused by an imprinting center defect (ICD, 
1–3%) or a paternal chromosomal translocation (0.1%) (1, 
2). The syndrome is characterized by hypotonia, behavioral 
challenges, typical dysmorphic features, and hypothalamic 
dysfunction resulting in hyperphagia, pituitary hormone 
deficiencies, abnormal temperature regulation, and inad-
equate pain registration (3–6).
Annual mortality in adults with PWS is high (3%) (7, 8) 
compared with 1.3% annual mortality in non-PWS adults 
with an intellectual disability (9). More than half of these 
deaths are caused by cardiopulmonary pathology (8, 10) 
and another 7% of deaths are directly related to obesity 
(8). Seventy-eight percent of deaths in patients with PWS 
are unexpected (11).
Multiple factors contribute to the increased risk of car-
diopulmonary pathology in patients with PWS. Based on our 
clinical experience with more than a hundred PWS adults, 
we hypothesize that there is a complex interaction between 
obesity and behavioral, endocrine, and cardiovascular (CV) 
risk factors that contribute to the high prevalence of cardio-
pulmonary disease in patients with PWS, as shown in Fig. 1.
Obesity in patients with PWS is caused by hyperphagia 
(leading to a high energy intake) combined with a low 
energy expenditure (12, 13). This low energy expend-
iture is caused by low muscle mass, which is part of the 
syndrome. Untreated pituitary hormone deficiencies like 
hypogonadism, hypothyroidism, and growth hormone de-
ficiency can affect muscle mass and function, causing a fur-
ther decrease in basal metabolic rate (12, 14–21).
The total energy expenditure in adults with PWS is 20% 
lower than in age-matched obese adults (22). This differ-
ence in energy expenditure should be compensated by either 
a strict diet or by exercising for at least 1 hour a day (23). 
However, exercise tolerance may be low, due to hypotonia, 
pituitary hormone deficiencies, and (severe) vitamin D defi-
ciency (14, 24–29). Moreover, the typical behavioral pheno-
type and musculoskeletal problems like scoliosis, hypotonia, 
and leg edema impair physical activity in adults with PWS. 
This results in a vicious circle of muscle weakness, exercise 
intolerance, and a further decrease in physical activity. The 
subsequent sedentary lifestyle can induce CV risk factors 
like hypertension, hypercholesterolemia, and type 2 dia-
betes mellitus (DM2) (30). Other CV risk factors often 
present in PWS are obesity hypoventilation syndrome and 
sleep apnea, which can be central sleep apnea, obstructive 
sleep apnea, or both. Central sleep apnea, obstructive sleep 
apnea, and obesity hypoventilation syndrome can lead to 
pulmonary hypertension (31, 32), DM2 (33), and a further 
increase in obesity (34) and CV risk (35–38). Lastly, the cog-
nitive phenotype of PWS (often higher verbal comprehen-
sion skills compared with performal/reasoning skills, which 
can easily lead to overestimation) and autism-related behav-
ioral challenges could induce stress. Stress can induce hyper-
tension, another important CV risk factor (39). Moreover, 
psychosis is prevalent in patients with PWS, often requiring 
psychiatric drugs. As many psychiatric drugs have CV side 
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The complex interplay between somatic and psycho-
logical factors requires a syndrome-specific approach to 
health problems. However, as PWS is a rare disorder (5), 
most physicians are unfamiliar with the syndrome and its 
associated comorbidities. Furthermore, the PWS-specific be-
havioral phenotype (high pain threshold and the inability 
to express complaints) often leads to underdiagnosis and 
undertreatment. Combined doctors’ and patients’ delay can 
lead to medical complications and hospital admission. Timely 
recognition of comorbidities can reduce medical complica-
tions and associated personal and financial burdens (41).
Previous authors have reported health problems in 
adults with PWS (11, 42–60). However, most of them 
did not perform a systematic screening and only re-
ported health problems that had already been diagnosed. 
As underdiagnosis is a serious problem in this patient 
population, the prevalences reported in these studies are 
most likely underestimated. Data from systematic health 
screenings in adults with PWS are scarce (44, 45, 47, 48, 
58) and little is known about the relation between pa-
tient characteristics (living situation, presence or absence 
of obesity, genotype, and demographic factors) and health 
problems. As a consequence, there is no consensus about 
periodical screening.
In our reference center, we routinely perform a system-
atic health screening in all adults with PWS in order to de-
tect comorbidities at an early stage. In this article, we report 
the prevalence of the physical health problems detected by 
our screening. Based on their associations with the afore-
mentioned patient characteristics, we provide practical ad-
vice for medical screening.
Methods
This study was approved by the Medical Ethics Committee 
of the Erasmus University Medical Center. In this retro-
spective study, we reviewed the medical files of all adults 
who visited the multidisciplinary outpatient clinic of the 
PWS reference center in the Erasmus University Medical 
Center, Rotterdam, Netherlands, between January 2015 
and April 2020 and who underwent a routine systematic 
health screening. All patients that visited our outpatient 
clinic were already diagnosed with PWS, often years be-
fore visiting our outpatient clinic and/or during childhood. 
Before the launch of our multidisciplinary outpatient clinic 
in 2015, many Dutch adults with PWS were treated by 
their general practitioner or physician for people with in-
tellectual disabilities (ID physician).
Our systematic screening consists of a structured 
interview, a complete physical examination, a medical 
questionnaire, a review of the medical records, biochem-
ical measurements and, if indicated and feasible, add-
itional tests such as dual energy X-ray absorptiometry 
(DEXA), polygraphy (PG), and polysomnography (PSG). 
We report the hidden health problems that were pre-


















































Figure 1. Factors contributing to cardiopulmonary disease in patients with PWS. Abbreviations: BMR, basal metabolic rate; diet ,dietitian; endo, 
endocrinologist; ID, physician for people with intellectual disabilities; LBM, lean body mass; OAHS, obesity associated hypoventilation syndrome; 
physio, physiotherapist; PWS, Prader-Willi syndrome; psych, psychologist. Legend: black arrows indicate a cause-and-effect relationship; dotted lines 
indicate an intervention; the stands for an intervention with medication; black borders indicate that the factor is inherent to the syndrome; dotted 
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of screening. Conditions that developed during later 
follow-up visits were not taken into account. Forty-two 
patients in the cohort that we describe were also men-
tioned in a previous study by Sinnema et  al (43), who 
gave an overview of 102 adults with PWS and the health 
problems that had already been diagnosed (without sys-
tematic screening).
Genetic diagnosis
We performed genetic testing or collected previous genetic 
test results from other Dutch academic hospitals to confirm 
the PWS diagnosis and to determine the genetic subtype.
Medical questionnaire
As part of regular patient care, primary caregivers filled 
out a medical questionnaire before visiting the outpatient 
clinic. This questionnaire included questions on the 
patient’s medical history, medication, family history, symp-
toms of disease, physical complaints, behavioral challenges, 
and social aspects such as school, relationships, and living 
situation. The symptoms of disease, physical complaints, 
and behavioral challenges are rated on a 5-point Likert 
scale (1 = rarely or never, 2 = not often and/or not severe, 
3 = quite often and/or quite severe, 4 = often and/or severe, 
5 = very often and/or very severe). A score of 3 or higher 
was considered clinically relevant and was further explored 
during the visit. Mutism is defined as the absence of speech.
Biochemical analysis
During the visit, blood samples were taken for general med-
ical screening, including the evaluation of fat metabolism 
(low density lipoprotein [LDL]-cholesterol), glucose me-
tabolism (nonfasting glucose, hemoglobin A1c), thyroid 
function (free T4), gonadal function (random luteinizing 
hormone [LH], follicle-stimulating hormone, estradiol or 
testosterone, sex hormone binding globulin), liver enzymes 
(aspartate transaminase, alanine transaminase, alkaline 
phosphatase, gamma glutamyl transpeptidase, total bilirubin, 
lactate dehydrogenase), kidney function (urea, creatinine, 
estimated glomerular filtration rate [eGFR]), the hemato-
poietic system (hemoglobin, hematocrit, mean corpuscular 
volume, leukocytes, thrombocytes and, in case of microcytic 
anemia, ferritin), and vitamin D status (25-hydroxyvitamin 
D). The eGFR is estimated by the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) formula.
Cutoff  levels. A hypercholesterolemia diagnosis was 
confirmed if the patient had a nonfasting LDL-cholesterol 
above 4.0 mmol/L. Type 2 diabetes mellitus was defined 
as a repeated fasting glucose above 6.7  mmol/L (or 
nonfasting glucose above 11.0  nmol/L). Hemoglobin 
A1c was used to assess long-term glycemic control. As 
hypothyroidism in PWS can be both primary and central 
(61), hypothyroidism was defined as a free T4 below 
11 pmol/L, regardless of thyroid stimulating hormone. 
Hypogonadism in males was defined as a morning 
testosterone level below 10.0  nmol/L or a random 
testosterone level below 10.0  nmol/L combined with 
clear clinical features of hypogonadism (sparse body hair, 
micropenis, and the absence of spontaneous morning 
erections). Hypogonadism in females was defined as 
absent, scarce, or irregular menses. The diagnosis of 
hypogonadism was based on both laboratory values and 
clinical parameters because of the effect of adipose tissue 
aromatase activity on estradiol and testosterone levels 
(62), and the fact that hypogonadism in PWS can be both 
primary and central (63). Due to intellectual disability in 
most patients, gynecological evaluation was not routinely 
performed. When females used oral contraceptives or 
estrogen replacement therapy before screening, we asked 
for the presence of the menstrual cycle before the start of 
estrogen replacement therapy.
Severe vitamin D deficiency was defined as a 
25-hydroxyvitamin D level below 20  nmol/L and a mild 
vitamin D deficiency was defined as a 25-hydroxyvitamin 
D level below 50 nmol/L. When patients used cholesterol-
lowering medications, oral antidiabetics, insulin, 
levothyroxine, or testosterone replacement therapy before 
the start of the screening, we requested pretreatment la-
boratory values to verify the diagnosis.
Additional tests
We screened for hypertension by measuring blood pressure. 
If the patient’s blood pressure was above 140/90 mmHg, 
the measurement was repeated, and if it was still elevated, 
a 30-minute blood pressure measurement was performed. 
If the patient already used antihypertensive drugs, we re-
quested pretreatment blood pressure values.
If risk factors for osteoporosis were present (untreated 
hypogonadism, family history of osteoporosis, previous 
fractures, untreated vitamin D deficiency, and/or cortico-
steroid treatment), we performed a DEXA scan to screen 
for osteoporosis or osteopenia. Osteoporosis was defined 
as a T-score (comparison of a person’s bone density with 
that of a healthy 30-year-old of the same sex) below -2.5, 
osteopenia was defined as a T-score between -1.0 and -2.5.
If there was a clinical suspicion of scoliosis (based on 
a gibbus deformity during physical examination), we per-
formed an X-ray of the spine if (1) the patient was not pre-
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from back pain, or (3) the caregivers reported new or pro-
gressive postural abnormalities. Radiologically confirmed 
scoliosis was defined as a Cobb angle of 10° or more, as 
measured on a spinal X-ray.
The indication for sleep studies was based on the presence 
of clinical signs of sleep apnea: severe snoring, witnessed 
apneas, daytime sleepiness, morning headaches, hyperten-
sion, or waking up with shortness of breath, headaches, or 
panic. If indicated and feasible, we performed PG (ie, the 
continuous recording of nasal airflow, thoracic and abdom-
inal movements, heart rate, and oxygen saturation during 1 
night) or a PSG (ie, PG measurements and electroencephal-
ography, electro-oculography, and electromyography). Also, 
before the start of growth hormone (GH) treatment, we per-
formed a PSG to exclude sleep apnea, as untreated sleep 
apnea is an absolute contraindication for GH treatment.
Data analysis
Statistical analysis was performed using R version 3.6.3. 
Descriptive statistics for continuous variables are reported 
as median and interquartile range (IQR). For dichotomous 
variables, we display the number of people and the per-
centage of total people, n (%). We used a chi-squared test 
to compare the prevalence of health problems between dif-
ferent groups based on patient characteristics: genotype, 
living situation, and gender. To investigate the relation-
ship between body mass index (BMI), age, patient char-
acteristics, and the prevalence of health problems, we used 
the Wilcoxon rank sum test. For the relationship between 
BMI, age, and living situation, we used the Kruskal-Wallis 
test. A chi-squared test for trend was used to compare the 
number of undiagnosed health problems between sub-
groups. To investigate the relationship between age and 
BMI, the Kendall rank correlation test was used. To investi-
gate the effect of BMI and age on health problems and the 
number of undiagnosed health problems corrected for age 
and BMI respectively, logistic and ordinal regression models 
were used and a likelihood ratio test was performed.
Literature review
We reviewed the literature for studies that report physical 
health problems in patients with PWS. Inclusion criteria 
were original research articles and observational studies 
that reported the prevalence of physical health problems in 
a cohort of patients with PWS of 15 years of age or older. 
Exclusion criteria were clinical trials, basic or translational 
research, case reports, case series that included less than 10 
adults with PWS, articles that were not available online, 
articles that were not available in English, and mixed pedi-
atric–adult articles that did not report separate prevalences 
for patients with PWS of 15 years of age or older. The full 
search strategy used is available upon request.
Results
We included 115 (56 male and 59 female) patients. Median 
age was 29 years (IQR 21–40) and median BMI 29 kg/m2  
(IQR 26–35). Baseline characteristics are shown in Table 1. 
Table 1. Baseline characteristicsof 115 adults with Prader-
Willi syndrome
Total, N = 115
Age in years, median [IQR] 29 [21–40]
BMI in kg/m2, median [IQR] 29 [26–35]
Male gender, n (%) 56 (49%)
Genetic subtype  
 Deletion, n (%) 64 (56%)
 mUPD, n (%)a 41 (36%)
 ICD, n (%) 3 (3%)
 Unknown, n (%) 7 (6%)
Growth hormone treatment  
 Only during childhood, n (%) 10 (9%)
 Only during adulthood, n (%) 3 (3%)
 Both, n (%) 40 (35%)
 Never, n (%) 62 (54%)
 Current growth hormone treatment, n (%) 41 (36%)
Use of hydrocortisone  
 Daily, n (%) 4 (4%)
 During physical or psychological stress, n (%) 47 (41%)




Use of levothyroxine, n (%) 17 (15%)
Living situation  
 With family, n (%) 28 (24%)
 In a specialized PWS group home, n (%) 23 (20%)
 In a non-specialized group home, n (%) 61 (53%)
 Assisted living, n (%) 3 (3%)
Scholar level  
 Secondary vocational education, n (%) 6 (5%)
 Prevocational secondary education, n (%) 3 (3%)
 Special education, n (%) 82 (71%)
 No education, n (%) 4 (4%)
 Unknown, n (%) 20 (17%)
Mutism, n (%) 3 (3%)
Relationship status  
 In a relationship with sexual intercourse, n (%) 8 (7%)
 In a relationship without sexual  
intercourse, n (%)
18 (16%)
 Not in a relationship, n (%) 76 (66%)
 Unknown, n (%) 13 (11%)
Abbreviations: BMI, body mass index; ICD, imprinting center defect; IQR, 
interquartile range; mUPD, maternal uniparental disomy; PWS, Prader-Willi 
syndrome. 
a In 11 patients with an mUPD, the parents were not available for genetic 
testing. Therefore, mUPD is the most likely genotype, but an ICD could not be 
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The exact age at diagnosis was known for 72 patients, 
of which 59 patients were diagnosed during childhood. 
Of 115 patients, 42 underwent transition after years of 
medical supervision at the pediatric multidisciplinary out-
patient clinic. All patients referred by the pediatrician had 
a personal care plan. Of the remaining 73 patients, 17 pa-
tients had been followed by an endocrinologist elsewhere 
during the year before the screening. A total of 46 patients 
had been followed by an ID physician and 14 had never 
visited an adult endocrinologist or ID physician before.
We refer to the repository (64) for the following supple-
mentary data: baseline characteristics and health problems 
by living situation and genotype; health problems by BMI, 
age, and gender; information about lifestyle, behavior, and 
physical complaints; details of biochemical analysis (liver 
panel, kidney function, hematopoiesis, and electrolyte 
values); and data about sleep apnea, bone mineral density, 
and vitamin D deficiency.
Health problems detected by screening
The results of our systematic health screening are shown 
in Table 2 and Fig. 2. We found undetected health prob-
lems in 61% of adults with PWS. One-fourth had more 
than 1 undetected simultaneous health problem. The most 
common undetected health problem was hypogonadism, 
which had gone unnoticed in 52% of males and 33% of fe-
males. Other undiagnosed health problems were scoliosis 
(20%), hypercholesterolemia (6%), DM2 (5%), hyperten-
sion (3%), and hypothyroidism (2%). Forty-five patients 
underwent DEXA scans as part of medical screening. 
This revealed 3 new cases of osteoporosis and 8 cases of 
osteopenia, on top of the 9 patients already known with 
osteoporosis and the 22 patients with osteopenia. Two 
males and 1 female (all older than 30 years of age during 
the screening) had osteoporosis despite previous treat-
ment for hypogonadism. Both males had received testos-
terone replacement therapy for more than 15 years before 
screening. For the female, the exact duration of estrogen 
replacement therapy was unknown. Nine patients were 
known to have sleep apnea before the screening. Nineteen 
patients underwent PG or PSG, of which 11 patients were 
diagnosed with sleep apnea.
Comparison of health problems between groups
Living situation. Twenty-three patients lived in a specialized 
PWS group home (PWS home), 61 in a nonspecialized 
group home (non-PWS home), 28 with family, and 3 in an 
assisted living facility. Patients living in non-PWS homes were 
significantly older (median age 36 years, IQR 28–50) than 
those living in PWS homes (median age 26 years, IQR 21–32) 
Table 2. Health problems in 115 adults with PWS before and after systematic screening
Total, N = 115
MissingBefore Screening Detected by Screening After Screening
Hypogonadism     
 Male (n = 56) 26 (48%) +52% 54 (100%) 2
 Female (n = 59) 26 (60%) +33% 40 (93%) 16a
Scoliosis 61 (54%) +20% 83 (74%)b 3
Hypercholesterolemia 14 (13%) +6% 22 (19%) 2
Type 2 diabetes mellitus 13 (12%) +5% 19 (17%) 2
Hypertension 17 (15%)c +3% 20 (18%) 3d
Hypothyroidism 17 (15%) +2% 19 (17%) 0
Vitamin D deficiency 26 (38%) +40% 54 (78%) 46e
 Severe vitamin D deficiency   8 (13%) 55
Total undiagnosed health problems     
 At least 1  70 (61%)   
 At least 2  28 (24%)   
 3 or more  10 (9%)   
Data are presented as n (% of total). In bold are the number and % of health problems detected by our systematic screening.
Abbreviation: PWS, Prader-Willi syndrome.
a (Caregivers of) 16 female patients did not recall whether they had had a normal menstrual cycle before the start of oral contraceptives or before reaching men-
opausal age. 
b Twenty-eight patients had clear scoliosis at physical examination, but X-ray was not performed due to practical/behavioral issues, and 55 cases were radiologi-
cally confirmed. 
c Four patients received antihypertensive medication before screening, but the indication was unknown. 
d Blood pressure was high in 2 patients, but the measurement was not repeated due to practical/behavioral issues. 
e In 2 patients vitamin D was not measured and 44 patients used vitamin D supplementation before the screening, but it was unknown whether they had low vi-
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or with family (median age 19 years, IQR 19–22). Body mass 
index and prevalence of hypertension were significantly 
higher in patients living in non-PWS homes (see Table 3).
Patients in PWS homes exercised more than those living 
with family or in non-PWS homes. Patients in PWS homes 
all exercised at least 30 minutes a day versus 75% and 
70% of those living with family or in non-PWS homes, 
respectively. A dietitian was involved in the care of 87% 
of patients living in PWS homes, 74% of those living in 
a non-PWS home, and 29% of those living with family.
Genotype. When comparing health problems between the 
2 largest genotypic subgroups (64 patients with a deletion 
and 41 with mUPD), scoliosis was more frequent in patients 
with a deletion than in patients with an mUPD (81% vs 
59%, P = 0.02). Other variables were not remarkably 
different between the genotypes (see Table 3).
Body mass  index. Body mass index increased with age 
(P = 0.02). Patients with a higher BMI had a higher total 
number of undiagnosed health problems (P < 0.001) and 
more hypercholesterolemia (P = 0.01) (see Table  4). This 
remained significant after correction for age.
Age. Older patients had a higher prevalence of 
DM2 (P < 0.001), hypertension (P < 0.001), and 
hypercholesterolemia (P < 0.002), and a higher total 
number of undiagnosed health problems (P = 0.001) (see 
Table  4). This remained significant after correction for 
BMI.
Gender. Body mass index was significantly higher in 
females than in males (P = 0.02). Hypothyroidism was 
more prevalent in females than in males (24% vs 9%, 
P = 0.03) (see Table 4).
Age and BMI. Thirteen patients had BMI < 25kg/m2 and 
age < 25 years. None of these patients had DM2, 1 patient 
had hypertension, and 2 had hypercholesterolemia (of 
which 1 case was undiagnosed before screening).
Fatigue and daytime sleepiness
Fatigue and daytime sleepiness were common. One-third 
of the patients (40/115) had clinically relevant daytime 
sleepiness (score of 3 or higher on a 5-point Likert scale). 
All of these 40 patients had either untreated vitamin D 
deficiency, untreated male hypogonadism (Table  5), or 
another treatable cause such as sleep apnea, narcolepsia, 
nycturia, or use of drugs that can cause sleepiness 
(antiepileptic drugs, antipsychotics, benzodiazepines, tri-
cyclic antidepressants, or antihistamines). Daytime sleepi-
ness was present in 62% of the patients with untreated 
vitamin D deficiency versus 36% of the patients with 
normal vitamin D levels (P = 0.02). It was also related to 
the severity of the deficieny: daytime sleepiness was pre-
sent in 80% of patients with untreated severe vitamin D 
defiency, 57% of patients with untreated mild vitamin 
D defiency, and 36% of patients with normal vitamin 
D levels.
Biochemical analysis
Liver panel was normal in most patients. However, 19 
patients had alkaline phosphatase levels above the upper 
limit of normal. The vast majority of them had potential 
underlying causes such as vitamin D deficiency (63%) and/
or obesity (58%). Normocytic anemia was common in 
males, but not in females. There were no cases of micro- 
or macrocytic anemia. Of the 17 males with anemia, 13 
(76%) had untreated hypogonadism. Creatinine levels 
were generally low: 35 males (63%) and 28 females (47%) 


































% revealed by screening % known before screening
Figure 2. Health problems detected by systematic health screening 
in 115 adults with PWS. Abbreviation: PWS, Prader-Willi syndrome. 
Legend: black bars indicate the percentage of health problems already 
diagnosed before the screening; gray bars indicate the percentage of 
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had creatinine levels below the lower limit of normal, and 
this was independent of BMI and age. Of all males, 95% 
had creatinine levels between 46 and 93µmol/L and eGFR 
levels between 93 and 149ml/min/1.73m2. Of all females, 
95% had creatinine levels between 37 and 76 µmol/L and 
eGFR levels between 98 and 140 ml/min/1.73m2.
Literature review
We found 21 publications reporting 1 or more of the fol-
lowing health problems in PWS: hypogonadism, hypo-
thyroidism, DM2, hypertension, hypercholesterolemia, 
scoliosis, vitamin D deficiency, sleep apnea, or osteopor-
osis/osteopenia. Outcomes of these studies are summarized 
in Tables 6 and 7. None of the papers reported the preva-
lence of vitamin D deficiency in PWS.
Algorithm for diagnostics and treatment
Based on our analysis of patients data and the literature re-
view, we defined diagnostic and therapeutic recommenda-
tions, presented in the algorithm in Fig. 3.
Discussion
We found a large number of undetected health problems 
among adults with PWS during our systematic health 
screening. To our knowledge, we are the first to translate 
this into an evidence-based algorithm for screening and 
treatment of adults with PWS. We hypothesize that the 
high prevalence of undiagnosed health problems is the re-
sult of most physicians’ unfamiliarity with the syndrome, 
in combination with the complex PWS-specific behavioral 
phenotype.
Previous studies
Previous studies have reported prevalences of health prob-
lems in adults with PWS. However, most studies (11, 42, 
43, 46, 49–53) did not perform a systematic screening. Of 
the 4 studies that performed a systematic health screening 
(44, 45, 47, 48, 58), only 2 (Laurier et al (44) and Coupaye 
et al (45)) included a substantial number of (over 20) pa-
tients. Six studies (54–57, 59, 60) performed a system-
atic screening, but focused on only 1 health problem of 
interest. Compared to the systematic screening described 













Age, median [IQR] 0 26 [21–32] 36 [28–50] 19 [19–22] <0.001 28 [21–36] 32 [21–49] 0.2
BMI, median [IQR] 0 27 [22–30] 30 [27–40] 28 [26–36] 0.004 31 [26–38] 29 [25–34] 0.3
Undiagnosed health 
problemsd
        
 At least one  9 (39%) 44 (72%) 15 (54%) 0.16 37 (58%) 25 (61%) 0.7
 At least two  2 (9%) 19 (31%) 5 (18%)  14 (22%) 12 (29%)  
 Three or more  2 (9%) 4 (7%) 4 (14%)  6 (9%) 3 (7%)  
Hypogonadism         
 Male (n = 56) 2 9 (100%) 28 (100%) 15 (100%) NAe 27 (100%) 19 (100%) NAe
 Female (n = 59) 16f 10 (100%) 20 (87%) 10 (100%) 0.2 25 (93%) 14 (93%) 0.9
Hypothyroidism 0 4 (17%) 12 (20%) 3 (11%) 0.6 11 (17%) 7 (17%) 0.99
Type 2 diabetes mellitus 2 2 (9%) 13 (22%) 3 (11%) 0.2 8 (13%) 10 (24%) 0.1
Hypertension 3 0 (0%) 17 (29%) 2 (7%) 0.002 9 (15%) 8 (20%) 0.5
Hypercholesterolemia 2 4 (17%) 15 (25%) 2 (7%) 0.1 11 (17%) 8 (20%) 0.7
Scoliosis 3 18 (78%) 44 (76%) 19 (68%) 0.6 51 (81%) 23 (59%) 0.02
Vitamin D deficiency 46g 14 (88%) 22 (85%) 16 (64%) NAh 33 (80%) 19 (76%) NAh
Data are presented as n (% of total). P-values <0.05 are bold.
Abbreviations: BMI, body mass index; IQR, interquartile range; mUPD, maternal uniparental disomy; PWS, Prader-Willi syndrome. 
a Patients living in a specialized Prader-Willi syndrome group home. 
b Patients living in a non-specialized group home. 
c Patients living with family. 
d Undiagnosed health problems are hypogonadism, hypothyroidism, type 2 diabetes mellitus, hypertension, hypercholesterolemia, scoliosis, and vitamin D 
deficiency. 
e Not applicable, as hypogonadism is present in 100%, regardless of patient characteristics.
 f (Caregivers of) 16 female patients did not recall whether they had had a normal menstrual cycle before the start of oral contraceptives or before reaching men-
opausal age. 
g In 2 patients, vitamin D was not measured, and 44 patients used vitamin D supplementation before the screening, but it was unknown whether they had low 
vitamin D values before the start of vitamin D supplementation. 
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by Laurier et al (44) and Coupaye et al (45), we found a 
lower prevalence of DM2, scoliosis, and hypothyroidism. 
The difference in the prevalence of DM2 could be partly 
explained by the large difference in BMI, which was much 
lower in our cohort than in the French cohorts (Table 7). 
Moreover, the patients in our cohort had more often been 
treated with GH during childhood. Although GH treat-
ment may have a short-term negative effect on glucose 
homeostasis due to increased insulin resistance, GH treat-
ment also improves body composition and exercise toler-
ance, which has positive effects on glucose metabolism in 
the long term (69–71).
Prader-Willi syndrome homes and 
non-PWS homes
Patients in specialized PWS homes had a lower BMI and 
a lower frequency of hypertension than patients living in 
non-PWS homes. This could probably be largely explained 
by the age difference between the groups. Another contrib-
uting factor could be that patients in a specialized PWS 
home are subject to strict supervision from trained per-
sonnel. In PWS homes, food is kept out of sight and food 
storages are locked. According to caregivers, this greatly 
reduces the stress and conflicts caused by food-seeking be-
havior. We hypothesize it might even prevent stress-related 
hypertension. The fact that all patients living in PWS homes 
received portion-controlled meals (as determined by a diet-
itian) and often exercised under supervision probably ex-
plained part of the difference in the BMI between patients 
living in PWS homes and those living in non-PWS homes.
Fatigue and daytime sleepiness
Fatigue and daytime sleepiness were very common prob-
lems among adults with PWS. According to caregivers, 
these complaints often prevented them from taking part 
in day trips and physical activities. Daytime sleepiness 
is usually attributed to a lack of hypothalamic arousal 
and is regarded as a problem that is inherent to the syn-
drome. However, when we looked in more detail, all pa-
tients with clinically relevant fatigue or daytime sleepiness 
had treatable underlying problems such as sleep apnea, 
narcolepsia, nycturia, vitamin D deficiency, untreated male 
hypogonadism, or use of drugs that can cause sleepiness. 
Although we could not perform a randomized controlled 
trial to assess whether treating these underlying problems 
resolved the complaints, our clinical experience is that the 
majority of the patients reported less fatigue after treat-
ment of the underlying cause. Also, caregivers reported 
that these patients were more actively participating in 
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Figure 3. Algorithm for diagnostics and treatment in adults with PWS. Abbreviations: BMI, body mass index; DEXA, dual energy X-ray absorpti-
ometry; FSH, follicle-stimulating hormone; FT4, free thyroxin; HbA1c, hemoglobin A1c; ITT, insulin tolerance test; LDL, low density lipoprotein; LH, 
luteinizing hormone; MTP, metyrapone test; PWS, Prader-Willi syndrome; SHBG, sex hormone binding globulin. aRecommendation based on expert 
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necessarily just “part of the syndrome”, but could be the 
symptom of an underlying, treatable problem. Treating the 
underlying cause is important to reduce daytime sleepiness 
and increase physical activity.
Vitamin D deficiency and hypogonadism
Both vitamin D deficiency and hypogonadism are fre-
quently present in adults with PWS. Low levels of vitamin 
D and testosterone are often attributed to obesity, as 
vitamin D is fat-soluble and testosterone production can 
be diminished by increased estradiol levels due to adi-
pose tissue aromatase activity. However, lean male pa-
tients also had hypogonadism and vitamin D defiency. 
Although there is no consensus on the clinical effects of 
vitamin D (25, 72–74), we found a clear relation between 
(the severity of) vitamin D deficiency and daytime sleepi-
ness. Although the cause of daytime sleepiness in this 
complex patient population is likely to be multifactorial, 
we believe that prescribing vitamin D may be beneficial 
for all PWS adults with vitamin D deficiency. The high 
prevalence of osteoporosis and osteopenia in adults with 
PWS combined with the fact that vitamin D knows little 
side effects (75) are additional arguments for treatment. 
Therefore, we recommend prescribing vitamin D supple-
mentation in all adults with PWS with a vitamin D level 
below 50 ng/mL.
Creatinine levels
Creatinine levels were low in the majority of patients, 
regardless of sex and BMI. This indicates that normal 
creatinine levels in patients with PWS are lower than in 
healthy controls, which is explained by their low muscle 
mass (13). Therefore, in PWS patients, presence of high-
normal creatinine levels might actually indicate impaired 
renal function. We recommend to adjust the reference 
values with –24% for males and –18% for females. In our 
hospital, the PWS-specific reference range for creatinine 
is 46 to 93  µmol/L (compared with 65–115  µmol/L for 
non-PWS adult males) and 37 to 76 µmol/L for females 
(compared with 55–90  µmol/L for non-PWS adult fe-
males). For the same reasons, we propose using PWS-
specific reference values for eGFR of >98 ml/min/1.73m2 
for PWS adult males and >93  ml/min/1.73m2 for PWS 
adult females.
Adrenal insufficiency
This is rare in adults with PWS (68). However, in cases 
of clinical signs of hypocortisolism, we recommend as-
sessing the hypothalamic-pituitary-adrenal axis using the 
metyrapone test or, in the absence of contraindications, the 
insulin tolerance test (see Fig. 3).
Strengths and limitations
Like every study, our study has strengths and limitations. 
The strengths of our study are the large sample size (con-
sidering the fact that PWS is a rare syndrome), its focus 
on adults, and the fact that we investigated health prob-
lems in relation to living situation, BMI, genotype, and 
demographic factors, thus making our study a powerful 
source of new information. Limitations may include se-
lection bias (due to selective referral to our specialized 
facility) and survival bias. Moreover, we have many 
missing values for osteoporosis and sleep apnea. These 
additional tests were not always performed because they 
were either not indicated or impossible to perform due 
to behavioral issues. Therefore, these results should be 
interpreted with caution.
Conclusion
We found undetected health problems in 61% of adults 
with PWS. On top of this, one-third of the patients had 
clinically relevant fatigue or daytime sleepiness which, ac-
cording to caregivers, prevented them from taking part in 
physical activities. Although daytime sleepiness is usually 
considered just “part of the syndrome,” all of these patients 
turned out to have treatable causes such as sleep apnea, 
narcolepsia, nycturia, vitamin D deficiency, untreated male 
hypogonadism, or use of drugs that can cause sleepiness. 
Therefore, fatigue and daytime sleepiness should be con-
sidered not just “part of the syndrome,” but the symptom 
of an underlying health problem. We recommend exploring 
and treating these underlying causes in order to optimize 
physical activity and prevent obesity-related cardiopul-
monary problems. We provide an algorithm for diagnostics 
and treatment, taking into account PWS-specific pitfalls 
like falsely low creatinine levels and false-normal cardiac 
markers. Use of the algorithm will optimize the mental 
and physical health of adults with PWS. This will improve 
exercise tolerance and reduce the personal and financial 
burden of cardiopulmonary complications in this vulner-
able patient group.
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